Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer

Alberto Martini, Giorgio Gandaglia, R. Jeffrey Karnes, Emanuele Zaffuto, Marco Bianchi, Paolo Gontero, Piotr Chlosta, Christian Gratzke, Markus Graefen, Derya Tilki, Vito Cucchiara, Vincenzo Mirone, Burkhard Kneitz, Rafael Sanchez Salas, Henk Van Der Poel, Bertrand Tombal, Martin Spahn, Thomas Steven Joniau, Francesco Montorsi, Alberto Briganti

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Background: Given the prolonged natural history of clinically localized, high-risk prostate cancer, there is a need for the identification of intermediate clinical endpoints (ICEs) to predict long-term overall survival (OS). Objective: To explore the role of novel potential ICEs based on clinical follow-up to predict long-term survival in patients with high-risk prostate cancer. Design, setting, and participants: Overall, 3507 patients treated at 12 tertiary referral centers between 1988 and 2016 were evaluated. Intervention: Radical prostatectomy (RP) with extended pelvic lymph node dissection. Outcome measurements and statistical analysis: The impact of biochemical recurrence (BCR) and clinical recurrence (CR) within 1, 3, 5, and 7 yr after surgery on the risk of OS was evaluated in multivariable Cox regression analyses. In patients with BCR, the impact of progression to CR within 6 mo and 1, 3, and 5 yr on long-term OS was investigated. Discrimination was assessed using Harrell's c index. Results and limitations: Median follow-up for survivors was 76 mo. The 5- and 10-yr OS and cancer-specific survival rates were 94% and 81% versus 98% and 95%, respectively. On a time-varying multivariable analysis, BCR (hazard ratio [HR]: 1.02; 95% confidence interval [CI]: 1.00, 1.04) and CR (HR: 1.05; 95% CI: 1.03–1.07) emerged as predictors of OS (p < 0.001). The development of CR within 5 yr after surgery was the most informative ICE for predicting OS (c index: 0.74). In patients with BCR, progression to CR within 12 mo represented the most informative predictor for the subsequent risk of dying from all causes. Patients who developed BCR within 5 yr after RP and progressed to CR within 12 mo had a 10-yr OS rate of 47%. These results require prospective validation. Conclusions: When predicting long-term survival in surgically treated high-risk patients, progression to CR within 5 yr of RP confers the highest discrimination with respect to other landmark points. In men experiencing BCR, progression to CR within the subsequent 12 mo achieved the highest discrimination. Further studies are needed to validate our findings. Patient summary: We investigated the most informative intermediate clinical endpoints for predicting overall survival (OS). Occurrence of clinical recurrence within 5 yr after radical prostatectomy confers the highest discrimination to a model predicting OS.

Original languageEnglish (US)
Pages (from-to)456-463
Number of pages8
JournalEuropean Urology Oncology
Volume2
Issue number4
DOIs
StatePublished - Jul 2019

Keywords

  • Biochemical recurrence
  • Clinical recurrence
  • Delta recurrence
  • Metastasis
  • Overall survival

ASJC Scopus subject areas

  • Surgery
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Urology

Fingerprint Dive into the research topics of 'Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer'. Together they form a unique fingerprint.

  • Cite this

    Martini, A., Gandaglia, G., Karnes, R. J., Zaffuto, E., Bianchi, M., Gontero, P., Chlosta, P., Gratzke, C., Graefen, M., Tilki, D., Cucchiara, V., Mirone, V., Kneitz, B., Sanchez Salas, R., Van Der Poel, H., Tombal, B., Spahn, M., Joniau, T. S., Montorsi, F., & Briganti, A. (2019). Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer. European Urology Oncology, 2(4), 456-463. https://doi.org/10.1016/j.euo.2018.12.002